1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia - Pipeline Review, H2 2020, provides an overview of the Spinocerebellar Ataxia (Genetic Disorders) pipeline landscape.
Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech and difficulty swallowing.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Spinocerebellar Ataxia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Spinocerebellar Ataxia (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1, 13 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Spinocerebellar Ataxia (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Spinocerebellar Ataxia (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionSpinocerebellar Ataxia - Overview
Spinocerebellar Ataxia - Therapeutics Development
Spinocerebellar Ataxia - Therapeutics Assessment
Spinocerebellar Ataxia - Companies Involved in Therapeutics Development
Spinocerebellar Ataxia - Drug Profiles
Spinocerebellar Ataxia - Dormant Projects
Spinocerebellar Ataxia - Discontinued Products
Spinocerebellar Ataxia - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Spinocerebellar Ataxia (SCA), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Allianz Pharmascience Ltd, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Anima Biotech Inc, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by BioXcel Corp, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Celavie Biosciences LLC, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Dystrogen Therapeutics SA, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Enzerna Biosciences LLC, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Everfront Biotech Inc, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Exicure Inc, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Gene Therapy Research Institution Co Ltd, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by IntraBio Ltd, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Ionis Pharmaceuticals Inc, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Lacerta Therapeutics Inc, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Sclnow Biotechnology Co Ltd, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Seelos Therapeutics, Inc., H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Shionogi & Co Ltd, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Spark Therapeutics Inc, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Steminent Biotherapeutics Inc, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Triplet Therapeutics Inc, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by UniQure NV, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Vico Therapeutics BV, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Vybion Inc, H2 2020
- Spinocerebellar Ataxia (SCA) - Pipeline by Wave Life Sciences Ltd, H2 2020
- Spinocerebellar Ataxia (SCA) - Dormant Projects, H2 2020
List of Figures
- Number of Products under Development for Spinocerebellar Ataxia (SCA), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allianz Pharmascience Ltd
- Anima Biotech Inc
- Biohaven Pharmaceutical Holding Company Ltd
- BioXcel Corp
- Celavie Biosciences LLC
- Dystrogen Therapeutics SA
- Enzerna Biosciences LLC
- Everfront Biotech Inc
- Exicure Inc
- Gene Therapy Research Institution Co Ltd
- IntraBio Ltd
- Ionis Pharmaceuticals Inc
- Lacerta Therapeutics Inc
- Sclnow Biotechnology Co Ltd
- Seelos Therapeutics, Inc.
- Shionogi & Co Ltd
- Spark Therapeutics Inc
- Steminent Biotherapeutics Inc
- Triplet Therapeutics Inc
- UniQure NV
- Vico Therapeutics BV
- Vybion Inc
- Wave Life Sciences Ltd
